SCHEMBL9905094

SCHEMBL9905094

O=C(CNC12CCC(F)(CC1)Cn1c2nc(C(=O)NCc2ccc(F)c(Cl)c2)c(O)c1=O)C(=O)N1CC[C@@H](F)C1

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.34
CYP2C9 P11712 1/20 0.34
DGAT1 O75907 1/20 0.34
MMP13 P45452 2/20 0.33
CXCR3 P49682 3/20 0.32
MYC P01106 2/20 0.31
WDR5 P61964 2/20 0.31
TRPV1 Q8NER1 1/20 0.31
MCHR1 Q99705 1/20 0.31
MAPK1 P28482 3/20 0.30
RPS6KA1 Q15418 1/20 0.30
PDE5A O76074 1/20 0.30
DPP4 P27487 1/20 0.30
DPP8 Q6V1X1 1/20 0.30
DPP9 Q86TI2 1/20 0.30
DPP7 Q9UHL4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9904920 0.92 KCNH2 (0.35) KCNH2CYP2C9MMP13MYCWDR5
SCHEMBL14119297 0.90 KCNH2 (0.42) KCNH2CYP2C9MMP13
SCHEMBL9905090 0.85 CYP2C9 (0.39) KCNH2CYP2C9DGAT1MMP13CXCR3
SCHEMBL9905000 0.82 KCNH2 (0.36) KCNH2CYP2C9MMP13MYCWDR5
SCHEMBL63674 0.79 KCNH2 (0.34) KCNH2CYP2C9DGAT1MMP13CXCR3
SCHEMBL9901778 0.78 CYP2C9 (0.42) KCNH2CYP2C9DGAT1MMP13WDR5
SCHEMBL9904916 0.77 CYP2C9 (0.40) KCNH2CYP2C9MMP13MYCWDR5
SCHEMBL9904944 0.77 MMP13 (0.39) KCNH2CYP2C9MMP13MYCWDR5
SCHEMBL9942910 0.74 CYP2C9 (0.48) KCNH2CYP2C9
SCHEMBL9901792 0.74 CYP2C9 (0.44) KCNH2CYP2C9DGAT1MMP13CXCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2649077-A1 HIV INTEGRASE INHIBITORS Bristol-Myers Squibb Company (US) 2013-10-16 EP claimed
US-20120309698-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2012-12-06 US claimed
WO-2012078834-A1 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-06-14 WO claimed
US-8835411-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-16 US disclosed
US-20120309698-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2012-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309698-A1 HIV Integrase Inhibitors DNTT, POLB, UNG KCNH2 3969/4885CYP2C9 602/4885DGAT1 3500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.